Human medicines European public assessment report (EPAR): Qaialdo, spironolactone, Date of authorisation: 26/05/2023, Revision: 2, Status: Authorised

PSUSA/00001158/202411

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 8, Status: Authorised

PRAC recommendations on signals adopted at the 7-10 July 2025 PRAC meeting

Human medicines European public assessment report (EPAR): Elahere, mirvetuximab soravtansine, Date of authorisation: 14/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Xaluprine (previously Mercaptopurine Nova Laboratories), mercaptopurine, Date of authorisation: 09/03/2012, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Date of authorisation: 17/07/2025, Status: Authorised